Advertisement

Gynecologic Cancers

  • A. C. EvansJr.
  • Daniel L. Clarke-Pearson

Abstract

Genital tract cancer afflicts a significant portion of postmenopausal women. These malignancies make up 13% of all cancers in females. Approximately 75,300 new cases were diagnosed and 25,200 deaths resulted from gynecologic cancers in 1994.1 Risk of developing a gynecologic cancer increases with age.2 Figures 24.1 and 24.2 show the age-related incidence and mortality of these malignancies. As with other cancers, early detection provides the best opportunity for successful management. Therapeutic strategies include surgery, chemotherapy, and radiation treatment. Integration of these divers modalities is the raison d’être of gynecologic oncologists, who possess skills necessary to accomplish surgical and medical treatment of these women as well as knowledge of appropriate circumstances for strategic use of radiotherapy.

Keywords

Ovarian Cancer Cervical Cancer Endometrial Cancer Obstet Gynecol Epithelial Ovarian Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Boring CC, Squires TS, Tong T, Montgomery S. Cancer statistics, 1994. CA Cancer J Clin. 1994; 44: 7–26.PubMedCrossRefGoogle Scholar
  2. 2.
    Ries LAG, Hankey BF, Miller BA, Hartman AM, Edwards BK. Cancer Statistics Review. NIH Pub. No. 91–2789. Bethesda, MD: National Cancer Institute; 1991.Google Scholar
  3. 3.
    Parazzini F, La Vecchia C, Bocciolone L, Franceschi S. The epidemiology of endometrial cancer. Gynecol Oncol. 1991; 41: 1–16.PubMedCrossRefGoogle Scholar
  4. 4.
    Friedlander M, de Souza P, Segelov E. Risk factors, epidemiology, screening, and prognostic factors in female genital cancer. Curr Opin Oncol. 1992; 4: 913–922.PubMedCrossRefGoogle Scholar
  5. 5.
    Kelsey JL, Whittemore AS. Epidemiology and primary prevention of cancers of the breast, endometrium, and ovary. A brief overview. Ann Epidemiol. 1994; 4: 89–95.PubMedCrossRefGoogle Scholar
  6. 6.
    Lawrence C, Tessaro I, Durgerian S, Caputo T, Richart RM, Greenwald P. Advanced-stage endometrial cancer: contributions of estrogen use, smoking, and other risk factors. Gynecol Oncol. 1989; 32: 41–45.PubMedCrossRefGoogle Scholar
  7. 7.
    Gambrell RD Jr, Bagnell CA, Greenblatt RB. Role of estrogens and progesterone in the etiology and prevention of endometrial cancer. Am J Obstet Gynecol. 1983; 146: 696–707.PubMedGoogle Scholar
  8. 8.
    Smith DC, Prentice R, Thompson DJ, Herrmann WL. Association of exogenous estrogen and endometrial carcinoma. N Engl J Med. 1975; 293: 1164–1167.PubMedCrossRefGoogle Scholar
  9. 9.
    Ziel HK, Finkle WD. Increased risk of endometrial carcinoma among users of conjugated estrogens. N Engl J Med. 1975; 293: 1167–1170.PubMedCrossRefGoogle Scholar
  10. 10.
    Seoud MA, Johnson J, Weed JC Jr. Gynecologic tumors in tamoxifen-treated women with breast cancer. Obstet Gynecol. 1993; 82: 165–169.PubMedGoogle Scholar
  11. 11.
    Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst. 1994; 86: 527–537.PubMedCrossRefGoogle Scholar
  12. 12.
    Quinn MA, Cauchi M, Fortune D. Endometrial carcinoma: steroid receptors and response to medroxyprogesterone acetate. Gynecol Oncol 1985; 21: 314–319.PubMedCrossRefGoogle Scholar
  13. 13.
    Centers for Disease Control. Oral contraceptive use and the risk of endometrial cancer. Cancer and Steroid Hormone Study. JAMA. 1983; 249: 1600–1604.CrossRefGoogle Scholar
  14. 14.
    Lawrence C, Tessaro I, Durgerian S, et al. Smoking, body weight, and early-stage endometrial cancer. Cancer. 1987; 59: 1665–1669.PubMedCrossRefGoogle Scholar
  15. 15.
    Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia. A long-term study of “untreated” hyperplasia in 170 patients. Cancer. 1985; 56: 403–412.PubMedCrossRefGoogle Scholar
  16. 16.
    Smith EM, Anderson B. Symptomatology, delay, and stage of disease in endometrial cancer. Cancer Detect Prev. 1987; 10: 247–254.PubMedGoogle Scholar
  17. 17.
    Walters D, Robinson D, Park RC, Patow WE. Diagnostic outpatient aspiration curettage. Obstet Gynecol. 1975; 46: 160–164.PubMedGoogle Scholar
  18. 18.
    Wikland M, Granberg S, Karlsson B. Replacing diagnostic curettage by vaginal ultrasound. Eur J Obstet Gynecol Reprod Biol. 1993; 49: 35–38.PubMedCrossRefGoogle Scholar
  19. 19.
    Hulka CA, Hall DA, McCarthy K, Simeone JF. Endometrial polyps, hyperplasia, and carcinoma in postmenopausal women: differentiation with endovaginal sonography. Radiology. 1994; 191: 755–758.PubMedGoogle Scholar
  20. 20.
    Cicinelli E, Comi N, Scorcia P, Petruzzi D, Epifani S. Hysteroscopy for diagnosis and treatment of endometrial adenocarcinoma precursors. A review of literature. Eur J Gynaecol Oncol. 1993; 14: 425–436.PubMedGoogle Scholar
  21. 21.
    Lindell LK, Anderson B. Routine pretreatment evaluation of patients with gynecologic cancer. Obstet Gynecol. 1987; 69: 242–246.PubMedGoogle Scholar
  22. 22.
    Hall KL, Dewar MA, Perchalski J. Screening for gynecologic cancer. Prim Care. 1992; 19: 607–620.PubMedGoogle Scholar
  23. 23.
    Morrow CP, Bundy BN, Kurman RJ, et al. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol 1991; 40: 55–65.PubMedCrossRefGoogle Scholar
  24. 24.
    Boronow RC, Morrow CP, Creasman WT, et al. Surgical staging in endometrial cancer: clinical-pathologic findings of a prospective study. Obstet Gynecol 1984; 63: 825–832.PubMedGoogle Scholar
  25. 25.
    Creasman WT, Morrow CP, Bundy BN, Homesley HD, Graham JE, Heller PB. Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study. Cancer. 1987; 60: 2035–2041.PubMedCrossRefGoogle Scholar
  26. 26.
    Sutton GP, Geisler HE, Stehman FB, Young PC, Kimes TM, Ehrlich CE. Features associated with survival and disease-free survival in early endometrial cancer. Am J Obstet Gynecol 1989;160:1385–1391; discussion 1391.Google Scholar
  27. 27.
    Palmer DC, Muir IM, Alexander Al, Cauchi M, Bennett RC, Quinn MA. The prognostic importance of steroid receptors in endometrial carcinoma. Obstet Gynecol 1988; 72: 388–393.PubMedGoogle Scholar
  28. 28.
    Creasman WT, McCarty KS Sr, Barton TK, McCarty KS Jr. Clinical correlates of estrogen-and progesterone-binding proteins in human endometrial adenocarcinoma. Obstet Gynecol 1980; 55: 363–370.PubMedGoogle Scholar
  29. 29.
    Sant Cassia LJ, Weppelmann B, Shingleton H, Soong SJ, Hatch K, Salter MM. Management of early endometrial carcinoma. Gynecol Oncol 1989; 35: 362–366.CrossRefGoogle Scholar
  30. 30.
    Cowles TA, Magrina JF, Masterson BJ, Capen CV. Comparison of clinical and surgical-staging in patients with endometrial carcinoma. Obstet Gynecol 1985; 66: 413–416.PubMedGoogle Scholar
  31. 31.
    Ferenczy A, Gelfand M. The biologic significance of cytologic atypia in progestin-treated endometrial hyperplasia. Am J Obstet Gynecol 1989; 160: 126–131.PubMedGoogle Scholar
  32. 32.
    Creasy GW, Kafrissen ME, Upmalis D. Review of the endometrial effects of estrogens and progestins. Obstet Gynecol Surv. 1992; 47: 654–678.PubMedCrossRefGoogle Scholar
  33. 33.
    Gal D, Edman CD, Vellios F, Forney JP. Long-term effect of megestrol acetate in the treatment of endometrial hyperplasia. Am J Obstet Gynecol 1983; 146: 316–322.PubMedGoogle Scholar
  34. 34.
    Wentz WB. Progestin therapy in lesions of the endometrium. Semin Oncol 1985; 12: 23–27.PubMedGoogle Scholar
  35. 35.
    Soper JT, Creasman WT, Clarke-Pearson DL, Sullivan DC, Vergadoro F, Johnston WW. Intraperitoneal chromic phosphate P 32 suspension therapy of malignant peritoneal cytology in endometrial carcinoma. Am J Obstet Gynecol 1985; 153: 191–196.PubMedGoogle Scholar
  36. 36.
    Piver MS, Hempling RE. A prospective trial of postoperative vaginal radium/cesium for grade 1–2 less than 50% myometrial invasion and pelvic radiation therapy for grade 3 or deep myometrial invasion in surgical stage I endometrial adenocarcinoma. Cancer. 1990; 66: 1133–1138.PubMedCrossRefGoogle Scholar
  37. 37.
    Morrow CP, Bundy BN, Homesley HD, et al. Doxorubicin as an adjuvant following surgery and radiation therapy in patients with high-risk endometrial carcinoma, stage I and occult stage II: a Gynecologic Oncology Group Study. Gynecol Oncol 1990; 36: 166–171.PubMedCrossRefGoogle Scholar
  38. 38.
    Kucera H, Vavra N, Weghaupt K. Benefit of external irradiation in pathologic stage I endometrial carcinoma: a prospective clinical trial of 605 patients who received postoperative vaginal irradiation and additional pelvic irradiation in the presence of unfavorable prognostic factors. Gynecol Oncol 1990; 38: 99–104.PubMedCrossRefGoogle Scholar
  39. 39.
    Underwood PB, Taylor PT. Endometrial carcinoma: the role of irradiation. Clin Obstet Gynecol 1986; 13: 767–787.Google Scholar
  40. 40.
    Martinez A, Podratz K, Schray M, Malkasian G. Results of whole abdominopelvic irradiation with nodal boost for patients with endometrial cancer at high risk of failure in the peritoneal cavity. A prospective clinical trial at the Mayo Clinic. Hematol Oncol Clin North Am. 1988; 2: 431–446.PubMedGoogle Scholar
  41. 41.
    Potish RA, Twiggs LB, Adcock LL, Savage JE, Levitt SH, Prem KA. Paraaortic lymph node radiotherapy. Obstet Gynecol 1985; 65: 251–256.PubMedGoogle Scholar
  42. 42.
    Loeffler JS, Rosen EM, Niloff JM, Howes AE, Knapp RC. Whole abdominal irradiation for tumors of the uterine corpus. Cancer. 1988; 61: 1332–1335.PubMedCrossRefGoogle Scholar
  43. 43.
    Potish RA, Twiggs LB, Adcock LL, Prem KA. Role of whole abdominal radiation therapy in the management of endometrial cancer; prognostic importance of factors indicating peritoneal metastases. Gynecol Oncol. 1985; 21: 80–86.PubMedCrossRefGoogle Scholar
  44. 44.
    Martinez A, Schray M, Podratz K, Stanhope R, Malkasian G. Postoperative whole abdomino-pelvic irradiation for patients with high risk endometrial cancer. Int J Radiat Oncol Biol Phys. 1989; 17: 371–377.PubMedCrossRefGoogle Scholar
  45. 45.
    Ahmad K, Kim YH, Deppe G, et al. Results of treatment in locally advanced carcinoma of the endometrium. Acta Oncol. 1990; 29: 203–209.PubMedCrossRefGoogle Scholar
  46. 46.
    Bonte J, Ide P, Billiet G, Wynants P. Tamoxifen as a possible chemotherapeutic agent in endometrial adenocarcinoma. Gynecol Oncol. 1981; 11: 140–161.PubMedCrossRefGoogle Scholar
  47. 47.
    Nyholm HC, Nielsen AL, Lyndrup J, Norup P, Thorpe SM. Biochemical and immunohistochemical estrogen and progesterone receptors in adenomatous hyperplasia and endometrial carcinoma: correlations with stage and other clinicopathologic features. Am J Obstet Gynecol. 1992; 167: 1334–1342.PubMedGoogle Scholar
  48. 48.
    Kauppila A. Oestrogen and progestin receptors as prognostic indicators in endometrial cancer. A review of the literature. Acta Oncol. 1989; 28: 561–566.CrossRefGoogle Scholar
  49. 49.
    Soper JT, Christensen CW. Steroid receptors and endometrial cancer. Clin Obstet Gynecol. 1986; 13: 825–842.Google Scholar
  50. 50.
    Piver MS, Fanning J, Baker TR. Phase II trial of cisplatin, Adriamycin, and etoposide for metastatic endometrial adenocarcinoma. Am J Clin Oncol. 1991; 14: 200–202.PubMedCrossRefGoogle Scholar
  51. 51.
    Thigpen T, Vance RB, Balducci L, Blessing J. Chemotherapy in the management of advanced or recurrent cervical and endometrial carcinoma. Cancer. 1981; 48: 658–665.PubMedCrossRefGoogle Scholar
  52. 52.
    Kosary CL. FIGO stage, histology, histologic grade, age and race as prognostic factors in determining survival for cancers of the female gynecological system: an analysis of 1973–87 SEER cases of cancers of the endometrium, cervix, ovary, vulva, and vagina. Semin Surg Oncol. 1994; 10: 31–46.PubMedCrossRefGoogle Scholar
  53. 53.
    Olt G, Berchuck A, Bast RC Jr. The role of tumor markers in gynecologic oncology. Obstet Gynecol Surv. 1990; 45: 570–577.PubMedCrossRefGoogle Scholar
  54. 54.
    Berchuck A, Soisson AP, Clarke-Pearson DL, et al. Immunohistochemical expression of CA 125 in endometrial adenocarcinoma: correlation of antigen expression with metastatic potential. Cancer Res. 1989; 49: 2091–2095.PubMedGoogle Scholar
  55. 55.
    Creasman WT. Recommendations regarding estrogen replacement therapy after treatment of endometrial cancer. Oncology (Huntington). 1992; 6: 23–26.Google Scholar
  56. 56.
    Greene MH, Clark JW, Blayney DW. The epidemiology of ovarian cancer. Semin Oncol. 1984; 11: 209–226.PubMedGoogle Scholar
  57. 57.
    Heintz AP, Hacker NF, Lagasse LD. Epidemiology and etiology of ovarian cancer: a review. Obstet Gynecol. 1985; 66: 127–135.PubMedGoogle Scholar
  58. 58.
    Rossing MA, Daling JR, Weiss NS, Moore DE, Self SG. Ovarian tumors in a cohort of infertile women. N Engl J Med. 1994; 331: 771–776.PubMedCrossRefGoogle Scholar
  59. 59.
    Piver MS, Baker TR, Jishi MF, et al. Familial ovarian cancer. A report of 658 families from the Gilda Radner Familial Ovarian Cancer Registry 1981–1991. Cancer. 1993; 71: 582–588.PubMedCrossRefGoogle Scholar
  60. 60.
    Amos CI, Struewing JP. Genetic epidemiology of epithelial ovarian cancer. Cancer. 1993; 71: 566–572.PubMedCrossRefGoogle Scholar
  61. 61.
    Lynch HT, Watson P, Lynch JF, Conway TA, Fili M. Hereditary ovarian cancer. Heterogeneity in age at onset. Cancer. 1993; 71: 573–581.PubMedCrossRefGoogle Scholar
  62. 62.
    Kurman RJ, ed. Blaustein’s Pathology of the Female Genital Tract. 4th ed. New York: Springer-Verlag; 1994.Google Scholar
  63. 63.
    Barber HR, Graber EA. The PMPO syndrome (postmenopausal palpable ovary syndrome). Obstet Gynecol. 1971; 38: 921–923.PubMedGoogle Scholar
  64. 64.
    Luxman D, Bergman A, Sagi J, David MP. The postmenopausal adnexal mass: correlation between ultrasonic and pathologic findings. Obstet Gynecol. 1991; 77: 726–728.PubMedGoogle Scholar
  65. 65.
    Buy JN, Ghossain MA, Sciot C, et al. Epithelial tumors of the ovary: CT findings and correlation with US. Radiology. 1991; 178: 811–818.PubMedGoogle Scholar
  66. 66.
    Malkasian GD Jr, Knapp RC, Lavin PT, et al. Preoperative evaluation of serum CA 125 levels in premenopausal and postmenopausal patients with pelvic masses: discrimination of benign from malignant disease. Am J Obstet Gynecol. 1988; 159: 341–346.PubMedGoogle Scholar
  67. 67.
    Podczaski E, Whitney C, Manetta A, et al. Use of CA 125 to monitor patients with ovarian epithelial carcinomas. Gynecol Oncol. 1989; 33: 193–197.PubMedCrossRefGoogle Scholar
  68. 68.
    van Nagell JR Jr, DePriest PD, Gallion HH, Pavlik EJ. Ovarian cancer screening. Cancer. 1993; 71: 1523–1528.PubMedCrossRefGoogle Scholar
  69. 69.
    DePriest PD, van Nagell JR Jr, Gallion HH, et al. Ovarian cancer screening in asymptomatic postmenopausal women. Gynecol Oncol. 1993; 51: 205–209.PubMedCrossRefGoogle Scholar
  70. 70.
    Barber HR. New frontiers in ovarian cancer diagnosis and management. Yale J Biol Med. 1991; 64: 127–141.PubMedGoogle Scholar
  71. 71.
    McGowan L. Patterns of care in carcinoma of the ovary. Cancer. 1993; 71: 628–633.PubMedCrossRefGoogle Scholar
  72. 72.
    Mayer AR, Chambers SK, Graves E, et al. Ovarian cancer staging: does it require a gynecologic oncologist? Gynecol Oncol. 1992; 47: 223–227.PubMedCrossRefGoogle Scholar
  73. 73.
    Griffiths CT. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr. 1975; 42: 101–104.PubMedGoogle Scholar
  74. 74.
    Hoskins WJ, McGuire WP, Brady MF, et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol. 1994; 170: 974–979.PubMedGoogle Scholar
  75. 75.
    Clarke-Pearson DL, DeLong ER, Chin N, Rice R, Creasman WT. Intestinal obstruction in patients with ovarian cancer. Variables associated with surgical complications and survival. Arch Surg. 1988; 123: 42–45.PubMedCrossRefGoogle Scholar
  76. 76.
    Omura G, Blessing JA, Ehrlich CE, et al. A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A Gynecologic Oncology Group Study. Cancer. 1986; 57: 1725–1730.PubMedCrossRefGoogle Scholar
  77. 77.
    McGuire WP. Taxol: a new drug with significant activity as a salvage therapy in advanced epithelial ovarian carcinoma. Gynecol Oncol 1993; 51: 78–85.PubMedCrossRefGoogle Scholar
  78. 77b.
    McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with pacitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New Engl J Med. 1996; 334: 1–6.PubMedCrossRefGoogle Scholar
  79. 78.
    Markman M. The role of intraperitoneal chemotherapy in ovarian cancer. Cancer Treat Res. 1994; 70: 73–82.PubMedCrossRefGoogle Scholar
  80. 79.
    Bookman MA. Biologic therapy in the management of refractory ovarian cancer. Gynecol Oncol 1993; 51: 113–126.PubMedCrossRefGoogle Scholar
  81. 80.
    Ozols RF, Young RC. Ovarian cancer. Curr Probl Cancer. 1987; 11: 57–122.PubMedCrossRefGoogle Scholar
  82. 81.
    Mangioni C, Bolis G, Pecorelli S, et al. Randomized trial in advanced ovarian cancer comparing cisplatin and carboplatin. J Natl Cancer Inst. 1989; 81: 1464–1471.PubMedCrossRefGoogle Scholar
  83. 82.
    Thyss A, Saudes L, Otto J, et al. Renal tolerance of cisplatin in patients more than 80 years old. J Clin Oncol 1994; 12: 2121–2125.PubMedGoogle Scholar
  84. 83.
    Soper JT, Wilkinson RH Jr, Bandy LC, Clarke-Pearson DL, Creasman WT. Intraperitoneal chromic phosphate P 32 as salvage therapy for persistent carcinoma of the ovary after surgical restaging. Am J Obstet Gynecol 1987; 156: 1153–1158.PubMedGoogle Scholar
  85. 84.
    Dembo AJ. Abdominopelvic radiotherapy in ovarian cancer. A 10-year experience. Cancer. 1985; 55: 2285–2290.PubMedCrossRefGoogle Scholar
  86. 85.
    Podczaski ES, Stevens CW Jr, Manetta A, Whitney CW, Larson JE, Mörtel R. Use of second-look laparotomy in the management of patients with ovarian epithelial malignancies. Gynecol Oncol 1987; 28: 205–214.PubMedCrossRefGoogle Scholar
  87. 86.
    Potter ME. Secondary cytoreduction in ovarian cancer: pro or con? Gynecol Oncol 1993; 51: 131–135.PubMedCrossRefGoogle Scholar
  88. 87.
    Carson LF, Rubin SC. Secondary cytoreduction— thoughts on the “pro” side. Gynecol Oncol 1993; 51: 127–130.PubMedCrossRefGoogle Scholar
  89. 88.
    Lund B, Jacobsen K, Rasch L, Jensen F, Olesen K, Feldt-Rasmussen K. Correlation of abdominal ultrasound and computed tomography scans with second-or third-look laparotomy in patients with ovarian carcinoma. Gynecol Oncol 1990; 37: 279–283.PubMedCrossRefGoogle Scholar
  90. 89.
    Ozols RF, Rubin SC, Dembo AJ, Robboy S. Epithelial ovarian cancer. In: Hoskins WJ, Perez CA, Young RC, eds. Principles and Practice of Gynecologic Oncology. 1st ed. Philadelphia: JB Lippincott; 1992: 731–781.Google Scholar
  91. 90.
    Friedman JB, Weiss NS. Second thoughts about second-look laparotomy in advanced ovarian cancer. N Engl J Med. 1990; 322: 1079–1082.PubMedCrossRefGoogle Scholar
  92. 91.
    de Souza PL, Friedlander ML. Prognostic factors in ovarian cancer. Hematol Oncol Clin North Am. 1992; 6: 761–782.PubMedGoogle Scholar
  93. 92.
    Young RC, Walton LA, Ellenberg SS, et al. Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials. N Engl J Med. 1990; 322: 1021–1027.PubMedCrossRefGoogle Scholar
  94. 93.
    Hightower RD, Nguyen HN, Averette HE, Hoskins WJ, Harrison T, Steren A. National survey of ovarian carcinoma IV: patterns of care and related survival for older patients. Cancer. 1994; 73: 377–383.PubMedCrossRefGoogle Scholar
  95. 94.
    Sutton GP, Stehman FB, Einhorn LH, Roth LM, Blessing JA, Ehrlich CE. Ten-year follow-up of patients receiving cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced epithelial ovarian carcinoma. J Clin Oncol 1989; 7: 223–229.PubMedGoogle Scholar
  96. 95.
    Ries LA. Ovarian cancer. Survival and treatment differences by age. Cancer. 1993; 71: 524–529.PubMedCrossRefGoogle Scholar
  97. 96.
    Yancik R. Ovarian cancer. Age contrasts in incidence, histology, disease stage at diagnosis, and mortality. Cancer. 1993; 71: 517–523.PubMedCrossRefGoogle Scholar
  98. 97.
    Markman M, Lewis JL Jr, Saigo P, et al. Epithelial ovarian cancer in the elderly. The Memorial Sloan-Kettering Cancer Center experience. Cancer. 1993; 71: 634–637.PubMedCrossRefGoogle Scholar
  99. 98.
    Gershenson DM, Mitchell MF, Atkinson N, et al. Age contrasts in patients with advanced epithelial ovarian cancer. The M.D. Anderson Cancer Center experience. Cancer. 1993; 71: 638–643.PubMedCrossRefGoogle Scholar
  100. 99.
    Steiner M, Rubinov R, Borovik R, Cohen Y, Robinson E. Multimodal approach (surgery, chemotherapy, and radiotherapy) in the treatment of advanced ovarian carcinoma. Cancer. 1985; 55: 2748–2752.PubMedCrossRefGoogle Scholar
  101. 100.
    Marchetti DL, Lele SB, Priore RL, McPhee ME, Hreshchyshyn MM. Treatment of advanced ovarian carcinoma in the elderly. Gynecol Oncol. 1993; 49: 86–91.PubMedCrossRefGoogle Scholar
  102. 101.
    Newcomb PA, Carbone PP. Cancer treatment and age: patient perspectives. J Natl Cancer Inst. 1993; 85: 1580–1584.PubMedCrossRefGoogle Scholar
  103. 102.
    Alberts DS, Dahlberg S, Green SJ, et al. Analysis of patient age as an independent prognostic factor for survival in a phase III study of cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in stages III (suboptimal) and IV ovarian cancer. A Southwest Oncology Group study. Cancer. 1993; 71: 618–627.PubMedCrossRefGoogle Scholar
  104. 103.
    Bicher A, Sarosy G, Kohn E, et al. Age does not influence taxol dose intensity in recurrent carcinoma of the ovary. Cancer. 1993; 71: 594–600.PubMedCrossRefGoogle Scholar
  105. 104.
    Fenoglio CM, Ferenczy A. Etiologic factors in cervical neoplasia. Semin Oncol 1982; 9: 349–372.PubMedGoogle Scholar
  106. 105.
    Brinton LA, Herrero R, Reeves WC, de Britton RC, Gaitan E, Tenorio F. Risk factors for cervical cancer by histology. Gynecol Oncol 1993; 51: 301–306.PubMedCrossRefGoogle Scholar
  107. 106.
    Winkelstein W Jr. Smoking and cervical cancer—current status: a review. Am J Epidemiol 1990; 131: 945–957.PubMedGoogle Scholar
  108. 107.
    Vermund SH, Kelley KF, Klein RS, et al. High risk of human papillomavirus infection and cervical squamous intraepithelial lesions among women with symptomatic human immunodeficiency virus infection. Am J Obstet Gynecol 1991; 165: 392–400.PubMedGoogle Scholar
  109. 108.
    Herrero R, Brinton LA, Reeves WC, et al. Sexual behavior, venereal diseases, hygiene practices, and invasive cervical cancer in a high-risk population. Cancer. 1990; 65: 380–386.PubMedCrossRefGoogle Scholar
  110. 109.
    La Vecchia C, Franceschi S, Decarli A, et al. Sexual factors, venereal diseases, and the risk of intraepithelial and invasive cervical neoplasia. Cancer. 1986; 58: 935–941.PubMedCrossRefGoogle Scholar
  111. 110.
    La Vecchia C, Decarli A, Fasoli M, et al. Dietary vitamin A and the risk of intraepithelial and invasive cervical neoplasia. Gynecol Oncol 1988; 30: 187–195.PubMedCrossRefGoogle Scholar
  112. 111.
    Brinton LA, Huggins GR, Lehman HF, et al. Long-term use of oral contraceptives and risk of invasive cervical cancer. Int J Cancer. 1986; 38: 399–344.CrossRefGoogle Scholar
  113. 112.
    Brinton LA, Hamman RF, Huggins GR, et al. Sexual and reproductive risk factors for invasive squamous cell cervical cancer. J Natl Cancer Inst. 1987; 79: 23–30.PubMedGoogle Scholar
  114. 113.
    Beral V, Hannaford P, Kay C. Oral contraceptive use and malignancies of the genital tract. Results from the Royal College of General Practitioners’ Oral Contraception Study. Lancet. 1988; 2: 1331–1335.PubMedCrossRefGoogle Scholar
  115. 114.
    Reeves WC, Rawls WE, Brinton LA. Epidemiology of genital papillomaviruses and cervical cancer. Rev Infect Dis. 1989; 11: 426–439.PubMedCrossRefGoogle Scholar
  116. 115.
    Schneider V, Kay S, Lee HM. Immunosuppression as a high-risk factor in the development of condyloma acuminatum and squamous neoplasia of the cervix. Acta Cytol. 1983; 27: 220–224.PubMedGoogle Scholar
  117. 116.
    Vonka V, Kanka J, Hirsch I, et al. Prospective study on the relationship between cervical neoplasia and herpes simplex type-2 virus. II. Herpes simplex type-2 antibody presence in sera taken at enrollment. Int J Cancer. 1984; 33: 61–66.PubMedCrossRefGoogle Scholar
  118. 117.
    Marshall JR, Graham S, Byers T, Swanson M, Brasure J. Diet and smoking in the epidemiology of cancer of the cervix. J Natl Cancer Inst. 1983; 70: 847–851.PubMedGoogle Scholar
  119. 118.
    Benedet JL, Anderson GH, Matisic JP. A comprehensive program for cervical cancer detection and management. Am J Obstet Gynecol. 1992; 166: 1254–1259.PubMedGoogle Scholar
  120. 119.
    Runowicz CD, Goldberg GL, Smith HO. Cancer screening for women older than 40 years of age. Obstet Gynecol Clin North Am. 1993; 20: 391–408.PubMedGoogle Scholar
  121. 120.
    De war MA, Hall K, Perchalski J. Cervical cancer screening. Past success and future challenge. Prim Care. 1992; 19: 589–606.Google Scholar
  122. 121.
    Fink DJ. Change in American Cancer Society Checkup Guidelines for detection of cervical cancer. CA Cancer J Clin. 1988; 38: 127–138.PubMedCrossRefGoogle Scholar
  123. 122.
    La Vecchia C, Franceschi S, Decarli A, Fasoli M, Gentile A, Tognoni G. “Pap” smear and the risk of cervical neoplasia: quantitative estimates from a case-control study. Lancet. 1984; 2: 779–782.PubMedCrossRefGoogle Scholar
  124. 123.
    Clarke EA, Anderson TW. Does screening by “Pap” smears help prevent cervical cancer? A case-control study. Lancet. 1979; 2: 1–4.PubMedCrossRefGoogle Scholar
  125. 124.
    Benedet JL, Miller DM, Nickerson KG. Results of conservative management of cervical intraepithelial neoplasia. Obstet Gynecol. 1992; 79: 105–110.PubMedGoogle Scholar
  126. 125.
    Bigrigg MA, Codling BW, Pearson P, Read MD, Swingler GR. Colposcopie diagnosis and treatment of cervical dysplasia at a single clinic visit. Experience of low-voltage diathermy loop in 1000 patients. Lancet. 1990; 336: 229–231.PubMedCrossRefGoogle Scholar
  127. 126.
    Hoffman MS, Sterghos S Jr, Gordy LW, Gunasekaran S, Cavanagh D. Evaluation of the cervical canal with the endocervical brush. Obstet Gynecol 1993; 82: 573–577.PubMedGoogle Scholar
  128. 127.
    Disaia PJ, Creasman WT. Clinical Gynecologic Oncology. 4th ed. St. Louis: Mosby; 1993.Google Scholar
  129. 128.
    Jones HW, 3d. Cone biopsy in the management of cervical intraepithelial neoplasia. Clin Obstet Gynecol 1983; 26: 968–979.PubMedCrossRefGoogle Scholar
  130. 129.
    Wright TC Jr., Gagnon S, Richart RM, Ferenczy A. Treatment of cervical intraepithelial neoplasia using the loop electrosurgical excision procedure. Obstet Gynecol 1992; 79: 173–178.PubMedGoogle Scholar
  131. 130.
    Koutsky LA, Galloway DA, Holmes KK. Epidemiology of genital human papillomavirus infection. Epidemiol Rev. 1988; 10: 122–163.PubMedGoogle Scholar
  132. 131.
    Taylor RR, Teneriello MG, Nash JD, Park RC, Birrer MJ. The molecular genetics of GYN malignancies. Oncology (Huntington). 1994; 8: 63–69.Google Scholar
  133. 132.
    Sevin BU, Nadji M, Averette HE, Hilsenbeck S, Smith D, Lampe B. Microinvasive carcinoma of the cervix. Cancer. 1992; 70: 2121–2128.PubMedCrossRefGoogle Scholar
  134. 133.
    Seski JC, Abell MR, Morley GW. Microinvasive squamous carcinoma of the cervix: definition, histologic analysis, late results of treatment. Obstet Gynecol 1977; 50: 410–414.PubMedGoogle Scholar
  135. 134.
    Jolles CJ, Freedman RS, Hamberger AD, Horbelt DV. Complications of extended-field therapy for cervical carcinoma without prior surgery. Int J Radiat Oncol Biol Phys. 1986; 12: 179–183.PubMedCrossRefGoogle Scholar
  136. 135.
    Disaia PJ. Surgical aspects of cervical carcinoma. Cancer. 1981; 48: 548–559.PubMedCrossRefGoogle Scholar
  137. 136.
    John M, Cooke JK, Flam M, Padmanabhan A, Mowry PA. Preliminary results of concomitant radiotherapy and chemotherapy in advanced cervical carcinoma. Gynecol Oncol 1987; 28: 101–110.PubMedCrossRefGoogle Scholar
  138. 137.
    Brenner DE, Gillette AW, Jones HW 3d, Burnett LS, Malcolm AW. Simultaneous radiation and chemotherapy for advanced carcinoma of the cervix. Gynecol Oncol 1987; 26: 381–385.PubMedCrossRefGoogle Scholar
  139. 138.
    Stehman FB, Bundy BN, Disaia PJ, Keys HM, Larson JE, Fowler WC. Carcinoma of the cervix treated with radiation therapy. I. A multi-variate analysis of prognostic variables in the Gynecologic Oncology Group. Cancer. 1991; 67: 2776–2785.PubMedCrossRefGoogle Scholar
  140. 139.
    Mettlin C, Mikutra JJ, Natarajan N, Priore R, Murphy GP. Treatment and follow-up study of squamous cell carcinoma in situ of the cervix uteri. Surg Gynecol Obstet. 1982; 155: 481–488.PubMedGoogle Scholar
  141. 140.
    Horiot JC, Pigneux J, Pourquier H, et al. Radiotherapy alone in carcinoma of the intact uterine cervix according to G. H. Fletcher guidelines: a French cooperative study of 1383 cases. Int J Radiat Oncol Biol Phys. 1988; 14: 605–611.PubMedCrossRefGoogle Scholar
  142. 141.
    Perez CA, Kurman RJ, Stehman FB, Thigpen JT. Uterine cervix. In: Hoskins WJ, Perez CA, Young RC, eds. Principles and Practice of Gynecologic Oncology. 1st ed. Philadelphia: JB Lippincott; 1992: 591–662.Google Scholar
  143. 142.
    Brookland RK, Rubin S, Danoff BF. Extended field irradiation in the treatment of patients with cervical carcinoma involving biopsy proven para-aortic nodes. Int J Radiat Oncol Biol Phys. 1984; 10: 1875–1879.PubMedCrossRefGoogle Scholar
  144. 143.
    Husseinzadeh N, Nahhas WA, Velkley DE, Whitney CW, Mörtel R. The preservation of ovarian function in young women undergoing pelvic radiation therapy. Gynecol Oncol 1984; 18: 373–379.PubMedCrossRefGoogle Scholar
  145. 144.
    Webb GA. The role of ovarian conservation in the treatment of carcinoma of the cervix with radical surgery. Am J Obstet Gynecol 1975; 122: 476–484.PubMedGoogle Scholar
  146. 145.
    Morley GW, Hopkins MP. Pelvic exenteration. In: Thompson JD, Rock JA, eds. Te Linde*s Operative Gynecology. 7th ed. Philadelphia: JB Lippincott; 1992: 1329–1345.Google Scholar
  147. 146.
    Magrina JF. Complications of irradiation and radical surgery for gynecologic malignancies. Obstet Gynecol Surv. 1993; 48: 571–575.PubMedCrossRefGoogle Scholar
  148. 147.
    Hopkins MP, Morley GW. Stage IB squamous cell cancer of the cervix: clinicopathologic features related to survival. Am J Obstet Gynecol 1991; 164: 1520–1527.PubMedGoogle Scholar
  149. 148.
    Hopkins MP, Morley GW. Radical hysterectomy versus radiation therapy for stage IB squamous cell cancer of the cervix. Cancer. 1991; 68: 272–277.PubMedCrossRefGoogle Scholar
  150. 149.
    Morley GW, Seski JC. Radical pelvic surgery versus radiation therapy for stage I carcinoma of the cervix (exclusive of microinvasion). Am J Obstet Gynecol 1976; 126: 785–798.PubMedGoogle Scholar
  151. 150.
    Carter J, Ramirez C, Waugh R, et al. Percutaneous urinary diversion in gynecologic oncology. Gynecol Oncol 1991; 40: 248–252.PubMedCrossRefGoogle Scholar
  152. 151.
    Sorbe B, Frankendal B. Bleomycin-Adriamycin-cisplatin combination chemotherapy in the treatment of primary advanced and recurrent cervical carcinoma. Obstet Gynecol 1984; 63: 167–170.PubMedGoogle Scholar
  153. 152.
    Giannone L, Brenner DE, Jones HW 3d, Greco FA, Burnett LS. Combination chemotherapy for patients with advanced carcinoma of the cervix: trial of mitomycin-C, vincristine, bleomycin, and cisplatin. Gynecol Oncol 1987; 26: 178–182.PubMedCrossRefGoogle Scholar
  154. 153.
    Muss HB, Jobson VW, Homesley HD, Welander C, Ferree C. Neoadjuvant therapy for advanced squamous cell carcinoma of the cervix: cisplatin followed by radiation therapy—a pilot study of the Gynecologic Oncology Group. Gynecol Oncol 1987; 26: 35–40.PubMedCrossRefGoogle Scholar
  155. 154.
    Hopkins MP, Morley GW. Prognostic factors in advanced stage squamous cell cancer of the cervix. Cancer. 1993; 72: 2389–2393.PubMedCrossRefGoogle Scholar
  156. 155.
    Kodama S, Kanazawa K, Honma S, Tanaka K. Age as a prognostic factor in patients with squamous cell carcinoma of the uterine cervix. Cancer. 1991; 68: 2481–2485.PubMedCrossRefGoogle Scholar
  157. 156.
    Levrant SG, Fruchter RG, Maiman M. Radical hysterectomy for cervical cancer: morbidity and survival in relation to weight and age. Gynecol Oncol 1992; 45: 317–322.PubMedCrossRefGoogle Scholar
  158. 157.
    Fuchtner C, Manetta A, Walker JL, Emma D, Berman M, Disaia PJ. Radical hysterectomy in the elderly patient: analysis of morbidity. Am J Obstet Gynecol 1992; 166: 593–597.PubMedGoogle Scholar
  159. 158.
    Geisler JP, Geisler HE. Radical hysterectomy in patients 65 years of age and older. Gynecol Oncol 1994; 53: 208–211.PubMedCrossRefGoogle Scholar
  160. 159.
    Brinton LA, Nasca PC, Maliin K, Baptiste MS, Wilbanks GD, Richart RM. Case-control study of cancer of the vulva. Obstet Gynecol 1990; 75: 859–866.PubMedGoogle Scholar
  161. 160.
    Carson LF, Twiggs LB, Okagaki T, Clark BA, Ostrow RS, Faras AJ. Human papillomavirus DNA in adeno-squamous carcinoma and squamous cell carcinoma of the vulva. Obstet Gynecol 1988; 72: 63–67.PubMedGoogle Scholar
  162. 161.
    Rusk D, Sutton GP, Look KY, Roman A. Analysis of invasive squamous cell carcinoma of the vulva and vulvar intraepithelial neoplasia for the presence of human papillomavirus DNA. Obstet Gynecol 1991; 77: 918–922.PubMedGoogle Scholar
  163. 162.
    Stehman FB, Bundy BN, Dvoretsky PM, Creasman WT. Early stage I carcinoma of the vulva treated with ipsilat-eral superficial inguinal lymphadenectomy and modified radical hemivulvectomy: a prospective study of the Gynecologic Oncology Group. Obstet Gynecol 1992; 79: 490–497.PubMedGoogle Scholar
  164. 163.
    Hopkins MP, Morley GW. Pelvic exenteration for the treatment of vulvar cancer. Cancer. 1992; 70: 2835–2838.PubMedCrossRefGoogle Scholar
  165. 164.
    Farias-Eisner R, Berek JS. Current management of invasive squamous carcinoma of the vulva. Clin Geriatr Med. 1993; 9: 131–143.PubMedGoogle Scholar
  166. 165.
    Lawton FG, Hacker NF. Surgery for invasive gynecologic cancer in the elderly female population. Obstet Gynecol 1990; 76: 287–289.PubMedGoogle Scholar
  167. 166.
    Kennedy AW, Flagg JS, Webster KD. Gynecologic cancer in the very elderly. Gynecol Oncol 1989; 32: 49–54.PubMedCrossRefGoogle Scholar
  168. 167.
    Snijders-Keilholz T, Trimbos JB, Hermans J, Leer JW. Management of vulvar carcinoma radiation toxicity, results and failure analysis in 44 patients (1980–1989). Acta Obstet Gynecol Scand. 1993; 72: 668–673.PubMedCrossRefGoogle Scholar
  169. 168.
    Hacker NF, Eifel P, McGuire W, Wilkinson EJ. Vulva. In: Hoskins WJ, Perez CA, Young RC, eds. Principles and Practice of Gynecologic Oncology. 1st ed. Philadelphia: JB Lippincott; 1992: 537–566.Google Scholar
  170. 169.
    Power EJ. Pap smears, elderly women, and Medicare. Cancer Invest. 1993; 11: 164–168.PubMedCrossRefGoogle Scholar
  171. 170.
    List ND, Kucuk O. Approaches to and effectiveness of current cancer interventions in the elderly. Oncology (Huntington). 1992; 6 (suppl): 31–38.Google Scholar
  172. 171.
    McGonigle KF, Lagasse LD, Karlan BY. Ovarian, uterine, and cervical cancer in the elderly woman. Clin Geriatr Med. 1993; 9: 115–130.PubMedGoogle Scholar
  173. 172.
    McKenna RJ Sr. Clinical aspects of cancer in the elderly. Treatment decisions, treatment choices, and follow-up. Cancer. 1994; 74: 2107–2117.PubMedCrossRefGoogle Scholar
  174. 173.
    Ganz PA. Does (or should) chronologic age influence the choice of cancer treatment. Oncology (Huntington). 1992; 6 (suppl): 45–47.Google Scholar
  175. 174.
    Ganz PA. Age and gender as factors in cancer therapy. Clin Geriatr Med. 1993; 9: 145–155.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1997

Authors and Affiliations

  • A. C. EvansJr.
  • Daniel L. Clarke-Pearson

There are no affiliations available

Personalised recommendations